The Effects of Allicor on Patients After Revascularization Treatment During a Year

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT05813171

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05813171
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05813171. Randomized; double masking; primary purpose treatment. Start 2023-04-20 (anticipated); primary completion 2024-04-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Allicor on Patients After Revascularization Treatment During a Year
Acronym
TEA-PARTY
Condition
Atherosclerosis
Condition
Peripheral Arterial Disease
Intervention (Dietary supplement)
Allicor
Intervention (Drug)
Placebo
Lead sponsor
Institute for Atherosclerosis Research, Russia (class: other)

Record details

Record id
cardio:ct-nct05813171
Content hash
2e14841a89f8b3296b9e72d6dee8d8a7e491bd954b99172c8d683e0bb2cebb73